AC BioScience

Pioneering a novel immunomodulator, poised to overcome immune escape in colorectal cancer (CRC) patients resistant to ICI therapy

About us

AC BioScience is a start-up biotech company headquartered at the Biopôle life sciences campus near Lausanne, with an innovative vision and business model.


AC BioScience is a pure play in immuno-oncology with focus on the development of its newly discovered drug to enhance the efficacy of Immune-checkpoint inhibitor (ICI) therapy.


Years of dedicated research by AC BioScience have yielded a robust portfolio of anti-cancer drugs, culminating in the discovery of ACB2112. The company is now channeling all resources towards the development of this groundbreaking therapeutic.


Archive of publications resulting from our research.